BioPharma Credit PLC (BPCR) - Net Assets
Based on the latest financial reports, BioPharma Credit PLC (BPCR) has net assets worth $1.15 Billion USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.16 Billion) and total liabilities ($7.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of BioPharma Credit PLC to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.15 Billion |
| % of Total Assets | 99.35% |
| Annual Growth Rate | 3.6% |
| 5-Year Change | -14.3% |
| 10-Year Change | N/A |
| Growth Volatility | 18.66 |
BioPharma Credit PLC - Net Assets Trend (2017–2024)
This chart illustrates how BioPharma Credit PLC's net assets have evolved over time, based on quarterly financial data. Also explore how large is BioPharma Credit PLC's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for BioPharma Credit PLC (2017–2024)
The table below shows the annual net assets of BioPharma Credit PLC from 2017 to 2024. For live valuation and market cap data, see BioPharma Credit PLC market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.18 Billion | -11.87% |
| 2023-12-31 | $1.34 Billion | +0.24% |
| 2022-12-31 | $1.34 Billion | -1.91% |
| 2021-12-31 | $1.36 Billion | -1.10% |
| 2020-12-31 | $1.38 Billion | -1.77% |
| 2019-12-31 | $1.40 Billion | +1.72% |
| 2018-12-31 | $1.38 Billion | +49.58% |
| 2017-12-31 | $922.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioPharma Credit PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $560.81 Million | 47.46% |
| Common Stock | $13.74 Million | 1.16% |
| Other Components | $607.12 Million | 51.38% |
| Total Equity | $1.18 Billion | 100.00% |
BioPharma Credit PLC Competitors by Market Cap
The table below lists competitors of BioPharma Credit PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Huizhou China Eagle Electronic Technology Co Ltd
SHE:002579
|
$1.06 Billion |
|
Safehold Inc
NYSE:SAFE
|
$1.06 Billion |
|
CRA International Inc
NASDAQ:CRAI
|
$1.06 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
$1.06 Billion |
|
Anhui Xinlong Electrical Co Ltd
SHE:002298
|
$1.06 Billion |
|
Elsight Ltd
AU:ELS
|
$1.06 Billion |
|
Green Cross Corp
KO:006280
|
$1.06 Billion |
|
Corbion N.V.
F:CSU
|
$1.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioPharma Credit PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,340,861,000 to 1,181,678,000, a change of -159,183,000 (-11.9%).
- Net income of 122,178,000 contributed positively to equity growth.
- Dividend payments of 174,662,000 reduced retained earnings.
- Share repurchases of 105,753,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $122.18 Million | +10.34% |
| Dividends Paid | $174.66 Million | -14.78% |
| Share Repurchases | $105.75 Million | -8.95% |
| Other Changes | $-946.00K | -0.08% |
| Total Change | $- | -11.87% |
Book Value vs Market Value Analysis
This analysis compares BioPharma Credit PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.97x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.78x to 0.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $1.20 | $0.94 | x |
| 2018-12-31 | $1.00 | $0.94 | x |
| 2019-12-31 | $1.02 | $0.94 | x |
| 2020-12-31 | $1.00 | $0.94 | x |
| 2021-12-31 | $0.99 | $0.94 | x |
| 2022-12-31 | $0.97 | $0.94 | x |
| 2023-12-31 | $1.02 | $0.94 | x |
| 2024-12-31 | $0.97 | $0.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioPharma Credit PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.34%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 98.17%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.02x
- Recent ROE (10.34%) is above the historical average (7.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 2.94% | 80.73% | 0.04x | 1.00x | $-65.09 Million |
| 2018 | 5.08% | 89.11% | 0.06x | 1.01x | $-67.86 Million |
| 2019 | 8.71% | 98.56% | 0.09x | 1.02x | $-18.05 Million |
| 2020 | 6.46% | 97.57% | 0.07x | 1.01x | $-48.76 Million |
| 2021 | 6.23% | 96.58% | 0.06x | 1.01x | $-51.41 Million |
| 2022 | 13.63% | 98.95% | 0.14x | 1.02x | $48.57 Million |
| 2023 | 8.09% | 67.92% | 0.12x | 1.01x | $-25.64 Million |
| 2024 | 10.34% | 98.17% | 0.10x | 1.02x | $4.01 Million |
Industry Comparison
This section compares BioPharma Credit PLC's net assets metrics with peer companies in the Asset Management industry.
Industry Context
- Industry: Asset Management
- Average net assets among peers: $745,852,800
- Average return on equity (ROE) among peers: 2.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioPharma Credit PLC (BPCR) | $1.15 Billion | 2.94% | 0.01x | $1.06 Billion |
| 3I Infrastructure PLC (3IN) | $1.20 Billion | 4.98% | 0.15x | $42.14 Million |
| Albion Enterprise VCT PLC (AAEV) | $61.87 Million | 11.55% | 0.03x | $3.29 Million |
| abrdn Asian Income Fund Limited (AAIF) | $431.87 Million | 14.17% | 0.08x | $5.17 Million |
| Abrdn Asia Focus PLC (AAS) | $98.67 Million | 9.82% | 0.09x | $7.49 Million |
| Albion Technology & General VCT PLC (AATG) | $64.83 Million | 5.63% | 0.01x | $3.22 Million |
| Abrdn PLC (ABDN) | $4.56 Billion | 10.22% | 39.48x | $45.21 Million |
| Aberdeen Diversified Income and Growth Trust PLC (ADIG) | $426.87 Million | 6.29% | 0.20x | $450.86K |
| Aquila Energy Efficiency Trust PLC (AEET) | $69.67 Million | -2.91% | 0.02x | $261.59K |
| Aquila European Renewables Income PLC (AERI) | $372.54 Million | -8.03% | 0.00x | $79.35 Million |
| Artemis UK Future Leaders plc (AFL) | $174.91 Million | -21.80% | 0.02x | $415.29 |
About BioPharma Credit PLC
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.